Literature DB >> 17703581

The role of GPCR dimerisation/oligomerisation in receptor signalling.

G Milligan1, M Canals, J D Pediani, J Ellis, J F Lopez-Gimenez.   

Abstract

A wide range of techniques have been employed to examine the quaternary structure of G-protein-coupled receptors (GPCRs). Although it is well established that homo-dimerisation is common, recent studies have sought to explore the physical basis of these interactions and the role of dimerisation in signal transduction. Growing evidence hints at the existence of higher-order organisation of individual GPCRs and the potential for hetero-dimerisation between pairs of co-expressed GPCRs. Here we consider how both homo-dimerisation/oligomerisation and hetero-dimerisation can regulate signal transduction through GPCRs and the potential consequences of this for function of therapeutic medicines that target GPCRs. Hetero-dimerisation is not the sole means by which co-expressed GPCRs may regulate the function of one another. Heterologous desensitisation may be at least as important and we also consider if this can be the basis for physiological antagonism between pairs of co-expressed GPCRs. Although there may be exceptions (Meyer et al. 2006), a great deal of recent evidence has indicated that most G-protein-coupled receptors (GPCRs) do not exist as monomers but rather as dimers or, potentially, within higher-order oligomers (Milligan 2004b; Park et al. 2004). Support for such models has been provided by a range of studies employing different approaches, including co-immunoprecipitation of differentially epitope-tagged but co-expressed forms of the same GPCR, co-operativity in ligand binding and a variety of resonance energy transfer techniques (Milligan and Bouvier 2005). Only for the photon receptor rhodopsin has the organisational structure of a GPCR been studied in situ. The application of atomic force microscopy to murine rod outer segment discs indicated that rhodopsin is organised in a series of parallel arrays of dimers (Liang et al. 2003) and based on this, molecular models were constructed to try to define and interpret regions of contact between the monomers (Fotiadis et al. 2004). Only for relatively few other GPCRs are details of the molecular basis of dimerisation available but within this limited data set, recent studies on the dopamine D2 receptor suggest a means by which information on the binding of an agonist can be transmitted between the two elements of the dimer via the dimer interface (Guo et al. 2005). Although the availability of cDNAs encoding molecularly defined GPCRs has allowed high-throughput screening for ligands that modulate GPCR function, this is performed almost exclusively in heterologous cell lines transfected to express only the specific GPCR of interest. Given that the human genome contains some 400-450 genes encoding non-chemosensory GPCRs, it is clear that any individual cell of the body may express a considerable number of GPCRs. Interactions between these, either via hetero-dimerisation, via heterologous desensitisation or via the integration of downstream signals can potentially alter the pharmacology, sensitivity and function of receptor agonists and hence produce varied responses. In this article, we will use specific examples to consider the role of homo-dimerisation/oligomerisation in GPCR function and whether either direct hetero-dimerisation or heterologous desensitisation between pairs of co-expressed GPCRs affects the function of the receptor pairs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17703581     DOI: 10.1007/2789_2006_007

Source DB:  PubMed          Journal:  Ernst Schering Found Symp Proc


  26 in total

Review 1.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Authors:  Terry P Kenakin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

3.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

4.  Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

Review 5.  Modeling of mammalian olfactory receptors and docking of odorants.

Authors:  Guillaume Launay; Guenhaël Sanz; Edith Pajot-Augy; Jean-François Gibrat
Journal:  Biophys Rev       Date:  2012-09-01

6.  CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.

Authors:  Fabien M Décaillot; Manija A Kazmi; Ying Lin; Sarmistha Ray-Saha; Thomas P Sakmar; Pallavi Sachdev
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

7.  Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans.

Authors:  Hui Zheng; Haibo Zou; Xiaopeng Liu; Ji Chu; Yali Zhou; Horace H Loh; Ping-Yee Law
Journal:  J Lipid Res       Date:  2012-02-29       Impact factor: 5.922

Review 8.  Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  IUBMB Life       Date:  2010-02       Impact factor: 3.885

9.  The systematic annotation of the three main GPCR families in Reactome.

Authors:  Bijay Jassal; Steven Jupe; Michael Caudy; Ewan Birney; Lincoln Stein; Henning Hermjakob; Peter D'Eustachio
Journal:  Database (Oxford)       Date:  2010-07-29       Impact factor: 3.451

10.  The role of ventral and dorsal striatum mGluR5 in relapse to cocaine-seeking and extinction learning.

Authors:  Lori A Knackstedt; Heather L Trantham-Davidson; Marek Schwendt
Journal:  Addict Biol       Date:  2013-05-27       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.